Generic Name and Formulations:
Cladribine 1mg/mL; soln for IV infusion after dilution; preservative-free.
Various generic manufacturers
Indications for Cladribine:
Active hairy cell leukemia.
Give by continuous IV infusion for 7 consecutive days. 0.09mg/kg per day.
See full labeling.
Administer under the supervision of a qualified physician experienced in the use of antineoplastic therapy. Risk of neurological toxicity. Acute nephrotoxicity has been observed with high doses (esp. when concomitant with other nephrotoxic treatments).
Delay or discontinue if neurotoxicity or renal toxicity occurs. Myelosuppression. Active infection. Renal or hepatic insufficiency. Monitor blood counts (esp. during first 4–8 weeks post-dose), renal and hepatic function. Pregnancy (Cat.D), nursing mothers: not recommended.
Chlorinated purine nucleoside analog.
Live attenuated vaccines: not recommended. Increased toxicity with myelosuppressive, immunosuppressive, or nephrotoxic agents.
Severe myelosuppression (eg, neutropenia, anemia, thrombocytopenia), fever, infection, fatigue, nausea, rash, headache, inj site reactions, others; neurotoxicity, nephrotoxicity, tumor lysis syndrome (rare).
Endocrinology Advisor Articles
- FDA Approves Marketing of 2 Devices to Detect Parathyroid Tissue in Real Time
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Diabetes Education Week 2018: Patient Resources for Your Practice
- Cardiometabolic Disease Patterns Related to Race, Ethnicity in Midlife Women
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D